Brief: Alligator Bioscience Q4 Oper Loss Widens To SEK 52.6 Mln
Feb 10 (Reuters) - Alligator Bioscience AB ATORX.ST :
* Q4 NET SALES SEK 20.1 MILLION VERSUS SEK 5.2 MILLION YEAR
AGO
* Q4 OPERATING LOSS SEK 52.6 MILLION VERSUS LOSS SEK 36.9
MILLION
YEAR AGO
* INTERIM RESULTS FROM MITAZALIMAB OPTIMIZE-1 PHASE 2 TRIAL
IN
PANCREATIC CANCER EXCEED 50% OBJECTIVE RESPONSE RATE
Source text for Eikon: ID:nMFN9rccB8
Further company coverage: ATORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alligator Bioscience AB
See all newsSweden's Alligator Bioscience Q3 sales fall as R&D winds down
Brief: Alligator Bioscience Q3 EBIT SEK -19.3 Million
Brief: Alligator Bioscience Appoints Johan Gileus As CEO
Brief: Alligator Bioscience Announces Final Outcome In Rights Issue
Brief: Alligator Bioscience To Initially Receive SEK 58.8 Mln From Rights Issue